Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2018 / N 2

Значение и место аналога глюкагоноподобного пептида-1 лираглутида в новой парадигме лечения сахарного диабета 2-го типа
М.Б. Анциферов, О.М. Котешкова

Список литературы

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015 Jan;38(1):140-9.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 Jun;281(21):2005-12.
3. Pharmacologic Approaches to Glycemic Treatment:Standards of Medical Care in Diabetes – 2018. American Diabetes Association. Diabetes Care 2018 Jan;41(Suppl 1):S73-S85.
4. Hædersdal S, Lund A, Knop FK, Vilsbøll T. The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clinic Proceedings 2018 Feb;93(2):217-39.
5. Gorgojo-Martínez JJ, Gargallo-Fernández MA, Brito-Sanfiel M, Lisbona-Catalán A. Real world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: the CIBELES project. International Journal of Clinical Practice 2018 Mar;72(3):e13055.
6. Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes, Obesity and Metabolism 2018 Feb;20 Suppl 1:22-33.
7. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism 2015 Feb;6(1):19-28.
8. Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2011 Jul;13(7):639-43.
9. Holst J.J. The physiology of glucagon-like peptide 1. Physiological Reviews 2007 Oct;87(4):1409-39.
10. Bastien-Dionne PO, Valenti L, Kon N, Gu W, Buteau J. Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion. Diabetes 2011 Dec;60(12):3217-22.
11. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2011;96:737-45.
12. Seghieri M, Rebelos E, Gastaldelli A, Astiarraga BD, Casolaro A, Barsotti E, Pocai A, Nauck M, Muscelli E, Ferrannini E. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 2013 Jan;56(1):156-61.
13. Villanueva-Peñacarrillo ML, Martín-Duce A, Ramos-Álvarez I, Gutiérrez-Rojas I, Moreno P, Nuche-Berenguer B, Acitores A, Sancho V, Valverde I, González N. Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients. Regulatory Peptides 2011 Jun;168(1-3):39-44.
14. Hayes MR, Leichner TM, Zhao S, Lee GS, Chowansky A, Zimmer D, De Jonghe BC, Kanoski SE, Grill HJ, Bence KK. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metabolism 2011 Mar;13(3):320-30.
15. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008 Dec;51(12):2263-70.
16. Aldiss P, Davies G, Woods R, Budge H, Sacks HS, Symonds ME. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. International Journal of Cardiology 2017 Feb;228:265-74.
17. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2016 Nov;375(19):1834-44.
18. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine 2016 Jul;375(4):311-22.
19. Watts GF, Chan DC. Novel insights into the regulation of postprandial lipemia by glucagon-like peptides: significance for diabetes. Diabetes 2013 Feb;62(2):336-8.
20. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009 Feb; 373(9662):473-81.
21. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009 Jul;374(9683):39-47.
22. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism 2017 Apr; 19(4):524-36.
23. Aroda VR, Brett J, Khutoryansky N, Ratner R. Identifying predictors of response to liraglutide in type 2 diabetes using recursive partitioning analysis. Presented at European Association for the Study of Diabetes (EASD) 48th Annual Meeting; 2012 Oct 01–05; Berlin, Germany.
24. Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B; BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes, Obesity and Metabolism 2014 Jul;16(7):636-44.
25. Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornøe K, Boopalan A, Nauck MA; NN2211-3917 Study Group. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism 2015 Nov;17(11):1056-64.
26. de Wit HM, Vervoort GM, Jansen HJ, de Grauw WJ, de Galan BE, Tack CJ. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). Diabetologia 2014 Sep;57(9):1812-9.
27. de Wit HM, Vervoort GM, Jansen HJ, de Galan BE, Tack CJ. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial. Journal of Internal Medicine 2016 Mar;279(3):283-92.
28. Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, Bosch-Traberg H, Kaku K. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. Journal of Diabetes Investigation 2016 Jul;7(4):565-73.
29. Li CJ, Li J, Zhang QM, Lv L, Chen R, Lv CF, Yu P, Yu DM. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovascular Diabetology 2012 Nov;11:142.
30. Vanderheiden A, Harrison L, Warshauer J, Li X, Adams-Huet B, Lingvay I. Effect of adding liraglutide vs placebo to a high-dose insulin regimen in patients with type 2 diabetes: a randomized clinical trial. JAMA Internal Medicine 2016 Jul;176(7):939-47.
31. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technology & Therapeutics 2011 May;13(5):592-5.
32. Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, Holst J, Nauck M. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism 2011 Jun;96(6):1695-702.
33. Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, Wang J, Yang JJ, Wang ZF, Tian F. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine 2016 Jun;52(3):516-26.
34. Chen WR, Tian F, Chen YD, Wang J, Yang JJ, Wang ZF, Da Wang J, Ning QX. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. International Journal of Cardiology 2016 Apr;208:109-14.
35. Wang X, Ding Z, Yang F, Dai Y, Chen P, Theus S, Singh S, Budhiraja M, Mehta JL. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together. Clinical Science (London) 2016 Aug;130(15): 1353-62.
36. Liu MM, Shen YE, Chen C. Lai XY, Zhang MY, Yu R. Protective effect of glucagon-like peptide-1 analogue on cardiomyocytes injury induced by hypoxia / reoxygenation. Zhonghua Neike Za Zhi [Chinese Journal of Internal Medicine] 2016 Apr; 55(4): 311-6.
37. Thornton SN, Regnault V, Lacolley P. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Nov 30;377(22):2196-7.
38. Funch D, Gydesen H, Tornøe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes, Obesity and Metabolism 2014 Mar;16(3):273-5.
39. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Hu N, Juurlink DN, Paterson JM, Targownik LE, Turin TC, Ernst P; and the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators, Suissa S, Dormuth CR5, Hemmelgarn BR, Teare GF, Caetano P, Chateau D, Henry DA, Paterson JM10, LeLorier J, Levy AR, Ernst P, Platt RW, Sketris IS. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Internal Medicine 2016;176(10):1464-73.
40. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P; Canadian Network for Observational Drug Effect Studies Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ 2016 Feb;352:i581.
41. Guo X, Yang Q, Dong J, Liao L, Zhang W, Liu F. Tumour risk with once-weekly glucagonlike peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Clinical Drug Investigation 2016 Jun;36(6):433-41.

References

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015 Jan;38(1):140-9.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 Jun;281(21):2005-12.
3. Pharmacologic Approaches to Glycemic Treatment:Standards of Medical Care in Diabetes – 2018. American Diabetes Association. Diabetes Care 2018 Jan;41(Suppl 1):S73-S85.
4. Hædersdal S, Lund A, Knop FK, Vilsbøll T. The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clinic Proceedings 2018 Feb;93(2):217-39.
5. Gorgojo-Martínez JJ, Gargallo-Fernández MA, Brito-Sanfiel M, Lisbona-Catalán A. Real world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: the CIBELES project. International Journal of Clinical Practice 2018 Mar;72(3):e13055.
6. Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes, Obesity and Metabolism 2018 Feb;20 Suppl 1:22-33.
7. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism 2015 Feb;6(1):19-28.
8. Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2011 Jul;13(7):639-43.
9. Holst J.J. The physiology of glucagon-like peptide 1. Physiological Reviews 2007 Oct;87(4):1409-39.
10. Bastien-Dionne PO, Valenti L, Kon N, Gu W, Buteau J. Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion. Diabetes 2011 Dec;60(12):3217-22.
11. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2011;96:737-45.
12. Seghieri M, Rebelos E, Gastaldelli A, Astiarraga BD, Casolaro A, Barsotti E, Pocai A, Nauck M, Muscelli E, Ferrannini E. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 2013 Jan;56(1):156-61.
13. Villanueva-Peñacarrillo ML, Martín-Duce A, Ramos-Álvarez I, Gutiérrez-Rojas I, Moreno P, Nuche-Berenguer B, Acitores A, Sancho V, Valverde I, González N. Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients. Regulatory Peptides 2011 Jun;168(1-3):39-44.
14. Hayes MR, Leichner TM, Zhao S, Lee GS, Chowansky A, Zimmer D, De Jonghe BC, Kanoski SE, Grill HJ, Bence KK. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metabolism 2011 Mar;13(3):320-30.
15. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008 Dec;51(12):2263-70.
16. Aldiss P, Davies G, Woods R, Budge H, Sacks HS, Symonds ME. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. International Journal of Cardiology 2017 Feb;228:265-74.
17. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2016 Nov;375(19):1834-44.
18. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine 2016 Jul;375(4):311-22.
19. Watts GF, Chan DC. Novel insights into the regulation of postprandial lipemia by glucagon-like peptides: significance for diabetes. Diabetes 2013 Feb;62(2):336-8.
20. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009 Feb; 373(9662):473-81.
21. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009 Jul;374(9683):39-47.
22. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism 2017 Apr; 19(4):524-36.
23. Aroda VR, Brett J, Khutoryansky N, Ratner R. Identifying predictors of response to liraglutide in type 2 diabetes using recursive partitioning analysis. Presented at European Association for the Study of Diabetes (EASD) 48th Annual Meeting; 2012 Oct 01-05; Berlin, Germany.
24. Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B; BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes, Obesity and Metabolism 2014 Jul;16(7):636-44.
25. Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornøe K, Boopalan A, Nauck MA; NN2211-3917 Study Group. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism 2015 Nov;17(11):1056-64.
26. de Wit HM, Vervoort GM, Jansen HJ, de Grauw WJ, de Galan BE, Tack CJ. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). Diabetologia 2014 Sep;57(9):1812-9.
27. de Wit HM, Vervoort GM, Jansen HJ, de Galan BE, Tack CJ. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial. Journal of Internal Medicine 2016 Mar;279(3):283-92.
28. Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, Bosch-Traberg H, Kaku K. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. Journal of Diabetes Investigation 2016 Jul;7(4):565-73.
Li CJ, Li J, Zhang QM, Lv L, Chen R, Lv CF, Yu P, Yu DM. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovascular Diabetology 2012 Nov;11:142.
30. Vanderheiden A, Harrison L, Warshauer J, Li X, Adams-Huet B, Lingvay I. Effect of adding liraglutide vs placebo to a high-dose insulin regimen in patients with type 2 diabetes: a randomized clinical trial. JAMA Internal Medicine 2016 Jul;176(7):939-47.
31. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technology & Therapeutics 2011 May;13(5):592-5.
32. Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, Holst J, Nauck M. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism 2011 Jun;96(6):1695-702.
33. Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, Wang J, Yang JJ, Wang ZF, Tian F. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine 2016 Jun;52(3):516-26.
34. Chen WR, Tian F, Chen YD, Wang J, Yang JJ, Wang ZF, Da Wang J, Ning QX. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. International Journal of Cardiology 2016 Apr;208:109-14.
35. Wang X, Ding Z, Yang F, Dai Y, Chen P, Theus S, Singh S, Budhiraja M, Mehta JL. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together. Clinical Science (London) 2016 Aug;130(15): 1353-62.
36. Liu MM, Shen YE, Chen C. Lai XY, Zhang MY, Yu R. Protective effect of glucagon-like peptide-1 analogue on cardiomyocytes injury induced by hypoxia / reoxygenation. Zhonghua Neike Za Zhi [Chinese Journal of Internal Medicine] 2016 Apr; 55(4): 311-6.
37. Thornton SN, Regnault V, Lacolley P. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Nov 30;377(22):2196-7.
38. Funch D, Gydesen H, Tornøe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes, Obesity and Metabolism 2014 Mar;16(3):273-5.
39. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Hu N, Juurlink DN, Paterson JM, Targownik LE, Turin TC, Ernst P; and the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators, Suissa S, Dormuth CR5, Hemmelgarn BR, Teare GF, Caetano P, Chateau D, Henry DA, Paterson JM10, LeLorier J, Levy AR, Ernst P, Platt RW, Sketris IS. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Internal Medicine 2016;176(10):1464-73.
40. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P; Canadian Network for Observational Drug Effect Studies Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ 2016 Feb;352:i581.
41. Guo X, Yang Q, Dong J, Liao L, Zhang W, Liu F. Tumour risk with once-weekly glucagonlike peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Clinical Drug Investigation 2016 Jun;36(6):433-41.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]